For the quarter ending 2025-09-30, CNTB made $16K in revenue. -$17,102K in net income. Net profit margin of -106887.50%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | |
|---|---|---|---|---|
| License and collaboration revenue | 16 | - | 6,508 | |
| Research and development expense | 11,110 | - | 7,314 | |
| General and administrative expense | 6,583 | - | 4,807 | |
| Total operating expenses | 17,693 | - | 12,121 | |
| Loss from operations | -17,677 | - | -5,613 | |
| Interest income | 545 | - | 1,113 | |
| Other income (expense) | -7 | - | 649 | |
| Total other income, net | 538 | - | 1,762 | |
| Net loss before income tax | -17,139 | -12,844 | -3,851 | |
| Income tax expense | 61 | 55 | 56 | |
| Net loss | -17,200 | -12,899 | -3,907 | |
| Foreign currency translation adjustments | 87 | 236 | -167 | |
| Unrealized gains on available-for-sale investments | 11 | -6 | 3 | |
| Comprehensive loss | -17,102 | -12,669 | -4,071 | |
| Basic net loss per ordinary share (in dollars per share) | -0.31 | -0.23 | -0.07 | |
| Diluted net loss per ordinary share (in dollars per share) | -0.31 | -0.23 | -0.07 | |
| Weighted-average ordinary shares outstanding, basic (in shares) | 55,716,000 | 55,498,000 | 13,803,250 | |
| Weighted-average ordinary shares outstanding, diluted (in shares) | 55,716,000 | 55,498,000 | 13,803,250 | |
Connect Biopharma Holdings Ltd (CNTB)
Connect Biopharma Holdings Ltd (CNTB)